The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.a

Pneumonitis (ILD)

Publications

Villavicencio C, Ramírez-Sarmiento A, Gayete A, Grau S, Orozco-Levi M

[Early pleuropulmonary toxicity associated with cabergoline, an antiparkinsonian drug].

Archivos de bronconeumologia 2007 Sep;43;519-22 — 2007 Sep — 519-22

Frans E, Dom R, Demedts M

Pleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline.

The European respiratory journal 1992 Feb;5;263-5 — 1992 Feb — 263-5